Cyclophosphamide Treatment Options

A collection of 2179 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.

Home

All Treatments

Cyclophosphamide

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

NCT00719888

Completed

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a dono... Read More

Gender:

ALL

Ages:

Between 6 months and 65 years

Trial Updated:

03/04/2025

Locations: University of Colorado Hospital, Aurora, Colorado +2 locations

Conditions: Acute Biphenotypic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma

Learn More ›

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

NCT05061017

Completed

The primary goal of this trial is to assess clinical response to nivolumab and pixatimod, and, nivolumab, pixatimod and cyclophosphamide in three separate patient cohorts. Cohort 1: MSS mCRC in combination with low-dose cyclophosphamide, Cohort 2: PD-1 relapsed/refractory melanoma, and Cohort 3: PD-1 relapsed/refractory NSCLC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma

Learn More ›

Natural Killer (NK) Cells in Combination with Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

NCT05400122

Recruiting

One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers. A safe way to give people with colorectal cancer and blood cancers fresh NK cells from a healthy donor has recently been discovered. The purpose of this study is to show that using two medicines (vactosertib and IL-2) with NK cells will be safe and will activate the donor NK cells. NK cell... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

Conditions: Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Syndrome, Plasma Cell Myeloma, Gastric Cancer, Esophageal Cancer, Esophagus Cancer, Gastric Cancer, Metastatic, Unresectable Esophageal Cancer, Metastatic Esophageal Cancer

Learn More ›

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

NCT01903330

Active Not Recruiting

This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: University of California, Irvine, Orange, California +2 locations

Conditions: Glioblastoma, Gliosarcoma

Learn More ›

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765

Recruiting

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa light chain antibody has been changed so instead of floating free in the blood, a part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymphoma cells is attached to the T cells. When an antibody is joined to a T cell in this way, it is called a chimeric receptor. The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR.κ.28 cells. These cells may be able to destroy lymphoma cancer cells. They do not, however, last very long in the body so their chances of fighting the cancer are unknown. Previous studies have shown that a new gene can be put into T cells to increase their ability to recognize and kill cancer cells. A gene is a unit of DNA. Genes make up the chemical structure carrying your genetic information that may determine human characteristics (i.e., eye color, height and sex). The new gene that is put in the T cells in this study makes an antibody called an anti-kappa light chain. This anti-kappa light chain antibody usually floats around in the blood. The antibody can detect and stick to cancer cells called lymphoma cells because they have a substance on the outside of the cells called kappa light chains. The purpose of this study is to determine whether receiving the ATLCAR.κ.28 cells is safe and tolerable and learn more about the side effects and how effective these cells are in fighting lymphoma. Initially, the study doctors will test different doses of the ATLCAR.κ.28, to see which dose is safer for use in lymphoma patients. Once a safe dose is identified, the study team will administer this dose to more patients, to learn about how these cells affect lymphoma cancer cells and identify other side effects they might have on the body. This is the first time ATLCAR.κ.28 cells are given to patients with lymphoma. The Food and Drug Administration (FDA), has not approved giving ATLCAR.κ.28 as treatment for lymphoma. This is the first step in determining whether giving ATLCAR.κ.28 to others with lymphoma in the future will help them. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

NCT06237881

Active Not Recruiting

To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

02/28/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms

Learn More ›

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934

Active Not Recruiting

Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease. The current treatment for this group of high-risk patients includes intensive multi-agent chemotherapy (induction) followed by myeloablative therapy with stem-cell rescue (consolidation) and then treatment of minimal residual disease (MRD) with isotretinoin. Recently a new standard of care was established by enhancing the treatment of MRD with the addition of a monoclonal antibody (ch14.18) which targets a tumor-associated antigen, the disialoganglioside GD2, which is uniformly expressed by neuroblasts. Despite improvement in 2-year event-free survival (EFS) of 20%, more than one-third of children with high-risk neuroblastoma (HR defined in) still cannot be cured by this approach. Therefore, novel therapeutic approaches are needed for this subset of patients. This study will be a pilot Phase II study of a unique anti-disialoganglioside (anti-GD2) monoclonal antibody (mAb) called hu14.18K322A, given with induction chemotherapy. PRIMARY OBJECTIVE: * To study the efficacy \[response: complete remission + partial remission (CR+PR)\] to two initial courses of cyclophosphamide and topotecan combined with hu14.18K322A (4 doses/course followed by GM-CSF) in previously untreated children with high-risk neuroblastoma. * To estimate the event-free survival of patients with newly diagnosed high-risk neuroblastoma treated with the addition of hu14.18K322A to treatment. SECONDARY OBJECTIVES: * To study the feasibility of delivering hu14.18K322A to 6 cycles induction chemotherapy and describe the antitumor activity (CR+PR) of this 6 course induction therapy. * To estimate local control and pattern of failure associated with focal intensity modulated or proton beam radiation therapy dose delivery in high-risk abdominal neuroblastoma. * To describe the tolerability of four doses of hu14.18K322A with allogeneic natural killer (NK) cells from an acceptable parent, in the immediate post-transplant period \[day +2 - +5 after peripheral blood stem cell (PBSC) infusion\] in consenting participants. * To describe the tolerability of hu14.18K322A with interleukin-2 and GM-CSF as treatment for minimal residual disease (MRD). Read Less

Gender:

ALL

Ages:

18 years and below

Trial Updated:

02/27/2025

Locations: St. Jude Children's Research Hospital, Memphis, Tennessee

Conditions: Neuroblastoma

Learn More ›

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

NCT05537766

Terminated

Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: City of Hope (City of Hope National Medical Center), Duarte, California +25 locations

City of Hope (City of Hope National Medical Center), Duarte, California

Stanford Cancer Institute, Stanford, California

Colorado Blood Cancer Institute, Denver, Colorado

Georgetown University Medical Centre, Washington, District of Columbia

University of Iowa, Iowa City, Iowa

Washington University School of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

The Ohio State University Wexner Medical Center - James Cancer HospitalS, Columbus, Ohio

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Tennessee Oncology, PLLC, Nashville, Tennessee

Vanderbilt University, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Medical University of Vienna, Department of Internal Medicine I, Div. of Hematology, Vienna, Not set

Hopital de la Pitie Salpetriere, Paris, Not set

Centre hospitalier de Toulouse - Hematology department, Toulouse Cedex 09, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Universitatsklinikum Koln, Koln, Not set

Universitatsklinikum Ulm, Ulm, Not set

IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedale di Perugia - Ospedale S. Maria della Misericordia, Perugia, Not set

Radboud University Nijmegen Medical Centre, Nijmegen, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Istituto Oncologico Della Svizzera Italiana (IOSI), Bellinzona, Not set

Conditions: Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma, Relapsed/Refractory Hairy Cell Leukemia

Learn More ›

A Novel "Pediatric-Inspired" Regimen with Reduced Myelosuppressive Drugs for Adults (aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

NCT01920737

Active Not Recruiting

The purpose of the study is to find out whether the combination of chemotherapy drugs that are routinely used in children with ALL, will be safe and effective in treating adult patients with ALL. The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps. In adult ALL there is no standard which drugs to give and how to combine them. Some leukemias have a chromosome abnormality called Philadelphia chromosome (also c... Read More

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

02/26/2025

Locations: Memorial Sloan Kettering Cancer Center, New York, New York +3 locations

Conditions: Leukemia

Learn More ›

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

NCT02828358

Completed

This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, e... Read More

Gender:

ALL

Ages:

364 days and below

Trial Updated:

02/26/2025

Locations: Children's Hospital of Alabama, Birmingham, Alabama +169 locations

Children's Hospital of Alabama, Birmingham, Alabama

USA Health Strada Patient Care Center, Mobile, Alabama

Providence Alaska Medical Center, Anchorage, Alaska

Banner Children's at Desert, Mesa, Arizona

Phoenix Childrens Hospital, Phoenix, Arizona

Arkansas Children's Hospital, Little Rock, Arkansas

Kaiser Permanente Downey Medical Center, Downey, California

Loma Linda University Medical Center, Loma Linda, California

Children's Hospital Los Angeles, Los Angeles, California

Cedars Sinai Medical Center, Los Angeles, California

Valley Children's Hospital, Madera, California

UCSF Benioff Children's Hospital Oakland, Oakland, California

Kaiser Permanente-Oakland, Oakland, California

Children's Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital Stanford University, Palo Alto, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

UCSF Medical Center-Mission Bay, San Francisco, California

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California

Children's Hospital Colorado, Aurora, Colorado

Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado

Connecticut Children's Medical Center, Hartford, Connecticut

Yale University, New Haven, Connecticut

Alfred I duPont Hospital for Children, Wilmington, Delaware

Children's National Medical Center, Washington, District of Columbia

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida

Nicklaus Children's Hospital, Miami, Florida

AdventHealth Orlando, Orlando, Florida

Arnold Palmer Hospital for Children, Orlando, Florida

Nemours Children's Hospital, Orlando, Florida

Nemours Children's Clinic - Pensacola, Pensacola, Florida

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida

Saint Mary's Medical Center, West Palm Beach, Florida

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia

Memorial Health University Medical Center, Savannah, Georgia

Kapiolani Medical Center for Women and Children, Honolulu, Hawaii

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Lurie Children's Hospital-Chicago, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Loyola University Medical Center, Maywood, Illinois

Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois

Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois

Saint Jude Midwest Affiliate, Peoria, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana

Blank Children's Hospital, Des Moines, Iowa

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

University of Kentucky/Markey Cancer Center, Lexington, Kentucky

Norton Children's Hospital, Louisville, Kentucky

Children's Hospital New Orleans, New Orleans, Louisiana

Ochsner Medical Center Jefferson, New Orleans, Louisiana

Eastern Maine Medical Center, Bangor, Maine

Maine Children's Cancer Program, Scarborough, Maine

Sinai Hospital of Baltimore, Baltimore, Maryland

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Walter Reed National Military Medical Center, Bethesda, Maryland

Tufts Children's Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

UMass Memorial Medical Center - University Campus, Worcester, Massachusetts

C S Mott Children's Hospital, Ann Arbor, Michigan

Henry Ford Health Saint John Hospital, Detroit, Michigan

Michigan State University Clinical Center, East Lansing, Michigan

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

Corewell Health Children's, Royal Oak, Michigan

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

University of Missouri Children's Hospital, Columbia, Missouri

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Cardinal Glennon Children's Medical Center, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Mercy Hospital Saint Louis, Saint Louis, Missouri

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

University Medical Center of Southern Nevada, Las Vegas, Nevada

Sunrise Hospital and Medical Center, Las Vegas, Nevada

Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada

Summerlin Hospital Medical Center, Las Vegas, Nevada

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Morristown Medical Center, Morristown, New Jersey

Saint Peter's University Hospital, New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

Saint Joseph's Regional Medical Center, Paterson, New Jersey

Albany Medical Center, Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

NYU Langone Hospital - Long Island, Mineola, New York

The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

Mount Sinai Hospital, New York, New York

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

University of Rochester, Rochester, New York

Stony Brook University Medical Center, Stony Brook, New York

State University of New York Upstate Medical University, Syracuse, New York

New York Medical College, Valhalla, New York

Mission Hospital, Asheville, North Carolina

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

East Carolina University, Greenville, North Carolina

Sanford Broadway Medical Center, Fargo, North Dakota

Children's Hospital Medical Center of Akron, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Dayton Children's Hospital, Dayton, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Legacy Emanuel Children's Hospital, Portland, Oregon

Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania

Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania

Geisinger Medical Center, Danville, Pennsylvania

Penn State Children's Hospital, Hershey, Pennsylvania

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Prisma Health Richland Hospital, Columbia, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota

T C Thompson Children's Hospital, Chattanooga, Tennessee

East Tennessee Childrens Hospital, Knoxville, Tennessee

The Children's Hospital at TriStar Centennial, Nashville, Tennessee

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Dell Children's Medical Center of Central Texas, Austin, Texas

Driscoll Children's Hospital, Corpus Christi, Texas

Medical City Dallas Hospital, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

El Paso Children's Hospital, El Paso, Texas

Cook Children's Medical Center, Fort Worth, Texas

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

Covenant Children's Hospital, Lubbock, Texas

UMC Cancer Center / UMC Health System, Lubbock, Texas

Children's Hospital of San Antonio, San Antonio, Texas

Methodist Children's Hospital of South Texas, San Antonio, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Scott and White Memorial Hospital, Temple, Texas

Primary Children's Hospital, Salt Lake City, Utah

University of Vermont and State Agricultural College, Burlington, Vermont

Inova Fairfax Hospital, Falls Church, Virginia

Children's Hospital of The King's Daughters, Norfolk, Virginia

Carilion Children's, Roanoke, Virginia

Seattle Children's Hospital, Seattle, Washington

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington

West Virginia University Charleston Division, Charleston, West Virginia

West Virginia University Healthcare, Morgantown, West Virginia

Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

Princess Margaret Hospital for Children, Perth, Western Australia

Perth Children's Hospital, Perth, Western Australia

CancerCare Manitoba, Winnipeg, Manitoba

Janeway Child Health Centre, Saint John's, Newfoundland and Labrador

IWK Health Centre, Halifax, Nova Scotia

Kingston Health Sciences Centre, Kingston, Ontario

Children's Hospital, London, Ontario

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital for Sick Children, Toronto, Ontario

The Montreal Children's Hospital of the MUHC, Montreal, Quebec

HIMA San Pablo Oncologic Hospital, Caguas, Not set

San Jorge Children's Hospital, San Juan, Not set

University Pediatric Hospital, San Juan, Not set

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

Learn More ›

CD123 Redirected T Cells for AML in Pediatric Subjects

NCT04678336

Recruiting

Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia (AML).

Gender:

ALL

Ages:

Between 1 year and 29 years

Trial Updated:

02/25/2025

Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory

Learn More ›

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

NCT02574728

Active Not Recruiting

This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.

Gender:

ALL

Ages:

Between 12 months and 30 years

Trial Updated:

02/25/2025

Locations: Phoenix Children's Hospital, Phoenix, Arizona +5 locations

Conditions: Cancer

Learn More ›